Incannex adds members to Clinical Advisory Board

Incannex Healthcare Inc. filed a current report to note that, on January 29, 2026, it announced additional appointments to its Clinical Advisory Board.

Accepted by SEC EDGAR 01/29/2026 - 08:04 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Incannex Healthcare Inc. filed a current report to note that, on January 29, 2026, it announced additional appointments to its Clinical Advisory Board. The company states that more details are provided in a press release, which is attached as Exhibit 99.1 and incorporated by reference into the filing.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Incannex Healthcare Inc. (IXHL) report in this 8-K filing?

Incannex Healthcare Inc. reported that on January 29, 2026, it announced additional appointments to its Clinical Advisory Board. Further details are contained in a press release attached as Exhibit 99.1 and incorporated by reference into the filing.

When did Incannex Healthcare Inc. announce the new Clinical Advisory Board appointments?

Incannex Healthcare Inc. announced the additional Clinical Advisory Board appointments on January 29, 2026. That same date is listed as the report date and earliest event date in the filing, aligning the disclosure with the announcement timing.

Where can investors find more detail on Incannex Healthcare’s new advisory appointments?

More detail is available in the press release identified as Exhibit 99.1 to the report. The company specifies that this exhibit, dated January 29, 2026, is incorporated by reference into Item 8.01, providing the primary description of the appointments.

What is the main purpose of this Incannex Healthcare (IXHL) Form 8-K?

The main purpose is to disclose an “Other Events” item concerning additional appointments to the company’s Clinical Advisory Board. The filing formally records the announcement and directs readers to an attached press release for detailed information.

Which exhibit in the Incannex Healthcare 8-K contains the press release?

Exhibit 99.1 contains the press release for Incannex Healthcare Inc. It is described as a press release dated January 29, 2026, and is specifically referenced in Item 8.01 as providing further information on the Clinical Advisory Board appointments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001873875 0001873875 2026-01-29 2026-01-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41106		93-2403210
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Rialto South Tower Level 23, 525 Collins Street Melbourne, VIC 3008 Australia		Not applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including Area Code: +61 409 840 786

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.0001 par value per share		IXHL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 29, 2026, Incannex Healthcare Inc. Announces Additional Appointments to Clinical Advisory Board. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Incannex Healthcare Inc., dated January 29, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Incannex Healthcare Inc.
Date: January 29, 2026		/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and President

2